全文获取类型
收费全文 | 1333篇 |
免费 | 86篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 59篇 |
妇产科学 | 32篇 |
基础医学 | 195篇 |
口腔科学 | 25篇 |
临床医学 | 111篇 |
内科学 | 196篇 |
皮肤病学 | 9篇 |
神经病学 | 109篇 |
特种医学 | 54篇 |
外科学 | 327篇 |
综合类 | 3篇 |
预防医学 | 60篇 |
眼科学 | 18篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 79篇 |
出版年
2023年 | 12篇 |
2022年 | 13篇 |
2021年 | 36篇 |
2020年 | 23篇 |
2019年 | 41篇 |
2018年 | 41篇 |
2017年 | 45篇 |
2016年 | 54篇 |
2015年 | 43篇 |
2014年 | 49篇 |
2013年 | 56篇 |
2012年 | 75篇 |
2011年 | 71篇 |
2010年 | 50篇 |
2009年 | 56篇 |
2008年 | 61篇 |
2007年 | 73篇 |
2006年 | 59篇 |
2005年 | 48篇 |
2004年 | 57篇 |
2003年 | 54篇 |
2002年 | 42篇 |
2001年 | 34篇 |
2000年 | 25篇 |
1999年 | 26篇 |
1998年 | 16篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 15篇 |
1992年 | 19篇 |
1991年 | 17篇 |
1990年 | 12篇 |
1989年 | 14篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1984年 | 4篇 |
1983年 | 8篇 |
1981年 | 4篇 |
1967年 | 4篇 |
1966年 | 4篇 |
1960年 | 4篇 |
1956年 | 4篇 |
1942年 | 3篇 |
1941年 | 4篇 |
1936年 | 4篇 |
1932年 | 6篇 |
1930年 | 3篇 |
排序方式: 共有1422条查询结果,搜索用时 0 毫秒
51.
52.
53.
Possible role of milky spots in mesothelial transplantation 总被引:1,自引:0,他引:1
Sacchi G Di Paolo N Venezia F Rossi A Nicolai GA Garosi G 《The International journal of artificial organs》2007,30(6):520-526
Milky spots are very small omental organs, in contact with peritoneal membrane, devoid of capsule and consisting of macrophages, lymphocytes and a few plasma cells supported by blood and lymphatic vessels. The exact role of these particular organs is still not clear, but they are similar to lymphatic structures and it is clear that they play a role in peritoneal infection and abdominal tumors. Peritoneal dialysis seems to activate the milky spots changing their morphology. The authors try to formulate some hypotheses on the role played by these little omental organs during autologous mesothelial transplant. 相似文献
54.
Daniele Borsetto Jonathan M. Fussey Diego Cazzador Joel Smith Andrea Ciorba Stefano Pelucchi Sara Don Paolo Boscolo‐Rizzo Michele Tomasoni Davide Lombardi Piero Nicolai Elisabetta Zanoletti Roberta Colangeli Enzo Emanuelli Max S. Osborne Syed F. Ahsan Margherita Tofanelli Giancarlo Tirelli Katherine McNamara Leonard Liew Katherine Harrison Ambrogio Fassina Samantha Sarcognato Neil Sharma Kanishka Rao Paul Pracy Paul Nankivell 《Head & neck》2020,42(3):522-529
55.
Stephan Sachs PhD Lili Niu PhD Philipp Geyer PhD Sigrid Jall PhD Maximilian Kleinert PhD Annette Feuchtinger PhD Kerstin Stemmer PhD Markus Brielmeier DVM Brian Finan PhD Richard D. DiMarchi PhD Matthias H. Tschöp MD Nicolai Wewer Albrechtsen PhD Matthias Mann PhD Timo D. Müller PhD Susanna M. Hofmann MD 《Diabetes, obesity & metabolism》2021,23(1):195-207
56.
Rune E. Kuhre PhD Carolyn F. Deacon DMSci Nicolai J. Wewer Albrechtsen PhD Jens J. Holst DMSci 《Diabetes, obesity & metabolism》2021,23(9):2009-2019
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) lower blood glucose and are used for treatment of type 2 diabetes. However, SGLT2is have been associated with increases in endogenous glucose production (EGP) by mechanisms that have been proposed to result from SGLT2i-mediated increases in circulating glucagon concentrations, but the relative importance of this effect is debated, and mechanisms possibly coupling SGLT2is to increased plasma glucagon are unclear. A direct effect on alpha-cell activity has been proposed, but data on alpha-cell SGLT2 expression are inconsistent, and studies investigating the direct effects of SGLT2 inhibition on glucagon secretion are conflicting. By contrast, alpha-cell sodium-glucose co-transporter-1 (SGLT1) expression has been found more consistently and appears to be more prominent, pointing to an underappreciated role for this transporter. Nevertheless, the selectivity of most SGLT2is does not support interference with SGLT1 during therapy. Paracrine effects mediated by secretion of glucagonotropic/static molecules from beta and/or delta cells have also been suggested to be involved in SGLT2i-induced increase in plasma glucagon, but studies are few and arrive at different conclusions. It is also possible that the effect on glucagon is secondary to drug-induced increases in urinary glucose excretion and lowering of blood glucose, as shown in experiments with glucose clamping where SGLT2i-associated increases in plasma glucagon are prevented. However, regardless of the mechanisms involved, the current balance of evidence does not support that SGLT2 plays a crucial role for alpha-cell physiology or that SGLT2i-induced glucagon secretion is important for the associated increased EGP, particularly because the increase in EGP occurs before any rise in plasma glucagon. 相似文献
57.
Kim K. B. Clemmensen MD Martin B. Blond PhD Hanan Amadid PhD Lea Bruhn MSc Dorte Vistisen PhD Kristian Karstoft PhD Frederik Persson DMSc Mathias Ried-Larsen PhD Jens J. Holst DMSc Nicolai J. Wewer Albrechtsen PhD Signe S. Torekov PhD Jonas S. Quist PhD Marit E. Jørgensen PhD Kristine Færch PhD 《Diabetes, obesity & metabolism》2021,23(2):530-539
58.
Nicolai A. Aksenov Alexander
V. Aksenov Alexander Kornienko Annelise De Carvalho Vronique Mathieu Dmitrii A. Aksenov Sergei N. Ovcharov Georgii D. Griaznov Michael Rubin 《RSC advances》2018,8(64):36980
A second generation polyphosphoric acid-mediated one-pot three-component synthesis of indoloquinoline scaffold is developed. This improved version of the process involves electrophilically activated nitroalkanes for the installation of strategic C–C and C–N bonds and ring C assembly. This modification allows the elimination of unnecessary solvent change operations and all steps are carried out in a true, uninterrupted one-pot manner. A further improvement involves the possibility to install an ortho-amino group in situ. A synthetic application of this method is showcased by the concise synthesis of an isocryptolepine alkaloid and its synthetic analogs with potent anticancer activities.An improved one-pot three-component synthesis involving electrophilically activated nitroalkanes allowed for efficient preparation of indoloquinolines with potent anticancer activities. 相似文献
59.
60.